Huborganoids
About Huborganoids
Huborganoids is a Healthcare company based in Netherlands, and was acquired by Merck in December 2024. Patient-derived organoid technology is provided for drug development services. Huborganoids offers products and services including Organoid Development and Drug Screening. Its focus areas include Medical Research Labs. Its legal entity is HUB Organoids B.V.
Company details
Provider of patient-derived organoid technology for drug development. It offers preclinical services and clinical trials using mini-organs in a dish to predict patient response to treatments. Services include drug screening, custom model and assay development, and licensing of its patented technology. The companys therapeutic areas encompass oncology, immuno-oncology, inflammatory diseases, genetic diseases, infectious diseases, and toxicology. This technology bridges the gap between laboratory research and clinical application, aiding in the reduction of drug attrition rates.
- Headquarters Netherlands
- Stage Acquired
- SectorsHealthcare
- Website huborganoids.nl
- Social LinkedIn
- Acquired by Merck (Dec 2024)
- Legal Name Hub Organoids B.V.
Products & Services of Huborganoids
Huborganoids offers a comprehensive portfolio of products and services, including Organoid Development and Drug Screening.
Patient-derived organoids are developed for use in drug screening and predictive modeling.
Drug responses are screened using organoid models to predict patient outcomes in preclinical settings.
Funding Insights of Huborganoids
- Total Rounds 2
- Last Round Grant — $762,285
- First Round $1.31M
(Jan 2018)
- Investors Count 1
All 2 funding rounds of Huborganoids with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $762,285 | Grant | – | – | |
| Jan 2018 | $1.31M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Huborganoids
Huborganoids has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany |
Investor details for Huborganoids
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Huborganoids
3 dated milestones of Huborganoids across 6 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Grant, of $762K.
- Exit Acquired by Merck.
Web traffic of Huborganoids
The website of Huborganoids (huborganoids.nl) receives about 8.5K visits a month.
- Monthly visits8.5K
▼ 3.9% vs previous month
Websites whose visitors overlap most with Huborganoids. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| crownbio.com | 100% | 77K | #441,040 | View details | |
| lifesciencenord.de | 88% | 15.4K | #2,162,650 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Huborganoids
Complete news archive for Huborganoids
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Huborganoids
Huborganoids is headquartered in Netherlands.
Provider of patient-derived organoid technology for drug development. It offers preclinical services and clinical trials using mini-organs in a dish to predict patient response to treatments. Services include drug screening, custom model and assay development, and licensing of its patented technology. The companys therapeutic areas encompass oncology, immuno-oncology, inflammatory diseases, genetic diseases, infectious diseases, and toxicology. This technology bridges the gap between laboratory research and clinical application, aiding in the reduction of drug attrition rates.
Huborganoids offers Organoid Development and Drug Screening.
Huborganoids has 2 investors. Key investors include Merck, and European Union.
Huborganoids operates through Hub Organoids B.V..
Yes. Huborganoids was acquired by Merck in December 2024.